Moorman C M, Hamilton A M
A.M.P. Hamilton, Medical Retina Service, Moorfields Eye Hospital, London, UK.
Eye (Lond). 1999 Apr;13 ( Pt 2):145-50. doi: 10.1038/eye.1999.41.
To evaluate the efficacy of the Iris Oculight MicroPulse 810 nm diode laser in the treatment of macular oedema secondary to either branch retinal vein occlusion (BRVO) or diabetic maculopathy and in the treatment of proliferative diabetic retinopathy. The specific advantages of this type of laser delivery are greater retinal pigment epithelial specificity and less damage to the inner retina, thus preserving visual field and colour contrast sensitivity.
Fifty-two eyes of 33 consecutive patients were treated over a 6-month period. Thirteen eyes had proliferative diabetic retinopathy and 39 had macular oedema secondary to BRVO or diabetic maculopathy. Panretinal and grid pattern photocoagulation were performed using the micropulse mode with the laser on for 100-300 microseconds and off for between 1900 and 1700 microseconds repeatedly in a pulse envelope of 0.1-0.3 s duration. Microaneurysms were not treated directly. Patients were assessed clinically and angiographically at 3 and 6 months.
Ten eyes (77%) with proliferative disease showed some regression of new vessels at 6 months. Twenty-two eyes (57%) showed resolution of macular oedema at 6 months. Visual acuity was maintained in 27 eyes (69%) and improved in 11 eyes (28%).
Diode laser in micropulse mode is effective in the management of diabetic and occlusive macular oedema and proliferative diabetic disease.
评估Iris Oculight MicroPulse 810纳米二极管激光治疗视网膜分支静脉阻塞（BRVO）或糖尿病性黄斑病变继发的黄斑水肿以及增殖性糖尿病视网膜病变的疗效。这种激光传输方式的特定优势在于对视网膜色素上皮的特异性更强，对视网膜内层的损伤更小，从而保留视野和颜色对比敏感度。
在6个月期间对33例连续患者的52只眼进行了治疗。13只眼患有增殖性糖尿病视网膜病变，39只眼患有BRVO或糖尿病性黄斑病变继发的黄斑水肿。使用微脉冲模式进行全视网膜和格栅样光凝，激光开启100 - 300微秒，关闭1900至1700微秒，在0.1 - 0.3秒的脉冲包络中反复进行。微动脉瘤未直接治疗。在3个月和6个月时对患者进行临床和血管造影评估。
10只（77%）患有增殖性疾病的眼睛在6个月时新生血管有一定程度的消退。22只（57%）眼睛在6个月时黄斑水肿消退。27只眼（69%）视力保持稳定，11只眼（28%）视力提高。
微脉冲模式的二极管激光在治疗糖尿病性和闭塞性黄斑水肿以及增殖性糖尿病疾病方面有效。
